ARNUITY ELLIPTA：市場規模・予測・市場洞察 (～2032年)

当レポートでは、主要7カ国 (米国、EU4カ国 (ドイツ、フランス、イタリア、スペイン)、英国、日本) における喘息治療薬 ARNUITY ELLIPTAの動向を調査し、治療薬の概要、作用機序、臨床開発データ、関連法規制、上市済みおよび開発中の薬剤との競合分析、国別の市場規模の推移・予測、SWOT分析、アナリストの見解などをまとめています。

レポートハイライト：

• 喘息の市場シナリオは、広範な研究と医療支出の増加により今後数年間で変化すると考えられています。
• 各社は、疾患を治療・改善し、課題を評価し、ARNUITY ELLIPTAの優位性に影響を与えられる機会を得るため、新しいアプローチに焦点を当てた治療薬の開発を行っています。
• 他の新興喘息治療薬がARNUITY ELLIPTAと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与える見通しです。
• 法規制上のマイルストーンと開発活動の詳細な説明により、喘息におけるARNUITY ELLIPTAの現在の開発シナリオを提供します。
• 2027年から2032年までのARNUITY ELLIPTAの予測販売データの詳細な分析により、喘息におけるARNUITY ELLIPTAの全体的なシナリオを明らかにし、治療薬ポートフォリオに関する意思決定プロセスを支援します。

目次

第1章 レポートイントロダクション

第2章 喘息におけるARNUITY ELLIPTA：概要

• 製品詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢 (上市済み治療薬)

第4章 競合情勢 (後期段階の新興治療薬)

第5章 ARNUITY ELLIPTA：市場評価

• 喘息におけるARNUITY ELLIPTA：市場の展望
• 主要7カ国の分析
  • 喘息治療薬 ARNUITY ELLIPTAの市場規模
• 国別市場分析
  • 市場規模：米国
  • 市場規模：ドイツ
  • 市場規模：英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ARNUITY ELLIPTA, Clinical Trial Description, 2023
• Table 2: ARNUITY ELLIPTA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: ARNUITY ELLIPTA Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ARNUITY ELLIPTA Market Size in the US, in USD million (2019-2032)
• Table 7: ARNUITY ELLIPTA Market Size in Germany, in USD million (2019-2032)
• Table 8: ARNUITY ELLIPTA Market Size in France, in USD million (2019-2032)
• Table 9: ARNUITY ELLIPTA Market Size in Italy, in USD million (2019-2032)
• Table 10: ARNUITY ELLIPTA Market Size in Spain, in USD million (2019-2032)
• Table 11: ARNUITY ELLIPTA Market Size in the UK, in USD million (2019-2032)
• Table 12: ARNUITY ELLIPTA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ARNUITY ELLIPTA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ARNUITY ELLIPTA Market Size in the United States, USD million (2019-2032)
• Figure 3: ARNUITY ELLIPTA Market Size in Germany, USD million (2019-2032)
• Figure 4: ARNUITY ELLIPTA Market Size in France, USD million (2019-2032)
• Figure 5: ARNUITY ELLIPTA Market Size in Italy, USD million (2019-2032)
• Figure 6: ARNUITY ELLIPTA Market Size in Spain, USD million (2019-2032)
• Figure 7: ARNUITY ELLIPTA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ARNUITY ELLIPTA Market Size in Japan, USD million (2019-2032)

"ARNUITY ELLIPTA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ARNUITY ELLIPTA for Asthma in the seven major markets. A detailed picture of the ARNUITY ELLIPTA for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ARNUITY ELLIPTA for Asthma. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ARNUITY ELLIPTA market forecast analysis for Asthma in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary:

ARNUITY ELLIPTA (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid (ICS) medicine for the maintenance treatment of asthma. Arnuity Ellipta is not indicated for the relief of acute bronchospasm. It reduces inflammation and helps prevent and control asthma symptoms.

• Dosage and administration

ARNUITY ELLIPTA should be administered only by the orally inhaled route. After inhalation, the patient should rinse their mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis. If symptoms arise between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief.

ARNUITY ELLIPTA should be administered as one inhalation once daily by the orally inhaled route. ARNUITY ELLIPTA should be used at the same time every day. Do not use ARNUITY ELLIPTA >1 time every 24 h.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ARNUITY ELLIPTA description, mechanism of action, dosage and administration, research and development activities in Asthma.
• Elaborated details on ARNUITY ELLIPTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ARNUITY ELLIPTA research and development activities in Asthma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around ARNUITY ELLIPTA.
• The report contains forecasted sales of ARNUITY ELLIPTA for Asthma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Asthma.
• The report also features the SWOT analysis with analyst views for ARNUITY ELLIPTA in Asthma.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARNUITY ELLIPTA Analytical Perspective by DelveInsight

• In-depth ARNUITY ELLIPTA Market Assessment

This report provides a detailed market assessment of ARNUITY ELLIPTA for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ARNUITY ELLIPTA Clinical Assessment

The report provides the clinical trials information of ARNUITY ELLIPTA for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARNUITY ELLIPTA dominance.
• Other emerging products for Asthma are expected to give tough market competition to ARNUITY ELLIPTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARNUITY ELLIPTA in Asthma.
• Our in-depth analysis of the forecasted sales data of ARNUITY ELLIPTA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ARNUITY ELLIPTA in Asthma.

Key Questions:

• What is the product type, route of administration and mechanism of action of ARNUITY ELLIPTA?
• What is the clinical trial status of the study related to ARNUITY ELLIPTA in Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARNUITY ELLIPTA development?
• What are the key designations that have been granted to ARNUITY ELLIPTA for Asthma?
• What is the forecasted market scenario of ARNUITY ELLIPTA for Asthma?
• What are the forecasted sales of ARNUITY ELLIPTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ARNUITY ELLIPTA for Asthma?
• Which are the late-stage emerging therapies under development for the treatment of Asthma?

Table of Contents

1. Report Introduction

2. ARNUITY ELLIPTA Overview in Asthma

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ARNUITY ELLIPTA Market Assessment

• 5.1. Market Outlook of ARNUITY ELLIPTA in Asthma
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ARNUITY ELLIPTA in the 7MM for Asthma
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ARNUITY ELLIPTA in the United States for Asthma
  • 5.3.2. Market Size of ARNUITY ELLIPTA in Germany for Asthma
  • 5.3.3. Market Size of ARNUITY ELLIPTA in France for Asthma
  • 5.3.4. Market Size of ARNUITY ELLIPTA in Italy for Asthma
  • 5.3.5. Market Size of ARNUITY ELLIPTA in Spain for Asthma
  • 5.3.6. Market Size of ARNUITY ELLIPTA in the United Kingdom for Asthma
  • 5.3.7. Market Size of ARNUITY ELLIPTA in Japan for Asthma

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options